23 completed, 5 terminated, 4 recruiting, 4 withdrawn. 38 Phase 2, 8 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 38 | Completed 23, Terminated 5, Recruiting 4, Withdrawn 4, Active not recruiting 2 |
| Phase 1 | 8 | Completed 5, Active not recruiting 2, Recruiting 1 |
Follow Sickle Cell Anemia: new trials by email Literature Review of Sickle Cell Anemia trials Research Report on Sickle Cell Anemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of SIL-8301 for Control of Hemolysis in a Uniform Sickle Cell Disease Endotype Senicapoc, Placebo - Sickle Cell Disease, Sickle Cell Anaemia | Phase 2 | Recruiting | Biossil Inc. | 105 | 2026-08-13 | 2026-08-17 |
| Alendronate for Osteonecrosis in Adults With Sickle Cell Disease Alendronate Sodium - Sickle Cell Disease, Sickle Cell Anemia | Phase 2 | Recruiting | University of California, Davis | 30 | 2026-03-09 | 2026-07-16 |
| Addition of JSP191 (C-kit Antibody) to Nonmyeloablative Hematopoietic Cell Transplantation for Sickle Cell Disease and Beta-Thalassemia TBI, Hydroxyurea, briquilimab - Sickle Cell Anemia, Beta Thalassemia | Phase 1 / Phase 2 | Active not recruiting | National Heart, Lung, and Blood Institute (NHLBI) | 40 | 2022-05-12 | 2026-03-12 |
| Management of Severe Acute Malnutrition in SCD, in Northern Nigeria hydroxyurea (20mg/kg/day), Ready-to-use therapeutic food - Sickle Cell Anemia, Severe Acute Malnutrition | Phase 2 | Completed | Vanderbilt University Medical Center | 132 | 2021-08-18 | 2024-03-27 |
| A Trial to Assess Haploidentical T-depleted Stem Cell Transplantation in Patients With SCD TCRα/β+ and CD19+ depleted haploidentical stem cell transplantation, Matched sibling donor transplantation - HbS Disease, Hemoglobin S Disease | Phase 2 | Recruiting | University of Regensburg | 212 | 2021-06-30 | 2024-05-13 |
| T-Cell Depleted Alternative Donor Bone Marrow Transplant for Sickle Cell Disease (SCD) and Other Anemias CD3/CD19 depleted leukocytes, CD45RA depleted leukocytes, Hydroxyurea - Sickle Cell Anemia, Beta-thalassemia Major | Phase 1 / Phase 2 | Recruiting | Paul Szabolcs | 5 | 2018-08-02 | 2026-08-13 |
| Hydroxyurea Management in Kids: Intensive Versus Stable Dosage Strategies Hydroxyurea - Sickle Cell Anemia | Phase 2 | Completed | St. Jude Children's Research Hospital | 58 | 2017-05-12 | 2021-06-25 |
| Study of Efficacy, Safety and Tolerability of ACZ885 (Canakinumab) in Pediatric and Young Adult Patients With Sickle Cell Anemia ACZ885, Placebo - Sickle Cell Anemia | Phase 2 | Completed | Novartis Pharmaceuticals | 49 | 2017-04-05 | 2026-01-13 |
| Study of Beet Juice for Patients With Sickle Cell Anemia beet juice (Unbeetable) - Sickle Cell Anemia | Phase 2 | Withdrawn | Wake Forest University Health Sciences | 2014-09-01 | 2018-08-02 | |
| EXTEND EXpanding Treatment for Existing Neurological Disease Hydroxyurea - Sickle Cell Anemia | Phase 2 | Completed | Children's Hospital Medical Center, Cincinnati | 43 | 2014-08-01 | 2025-08-22 |
| Gum Arabic as Fetal Hemoglobin Agent in Sickle Cell Anemia Gum Arabic - Sickle Cell Anemia | Phase 1 / Phase 2 | Completed | Al-Neelain University | 47 | 2014-04-01 | 2015-06-10 |
| The Effect of Rivaroxaban in Sickle Cell Disease rivaroxaban, placebo - Sickle Cell Anemia, Sickle Cell-Beta0-Thalassemia | Phase 2 | Completed | University of North Carolina, Chapel Hill | 14 | 2014-02-01 | 2020-04-13 |
| Risk-based Therapy for Sickle Cell Anemia: A Feasibility Study Hydroxyurea, Placebo - Sickle Cell Anemia | Phase 2 | Withdrawn | Children's National Research Institute | 2014-02-01 | 2017-10-18 | |
| Phase 2 Study of MP4CO to Treat Vaso-occlusive Sickle Crisis MP4CO, Sodium chloride solution - Anemia, Sickle Cell, Sickle Cell Anemia | Phase 2 | Withdrawn | Sangart | 2013-10-01 | 2013-10-28 | |
| A Phase II Trial of Regadenoson in Sickle Cell Anemia Regadenoson, Placebo - Sickle Cell Anemia | Phase 2 | Completed | Dana-Farber Cancer Institute | 100 | 2013-07-01 | 2018-02-07 |
| A Pilot Study of N-acetylcysteine in Patients With Sickle Cell Disease N-Acetylcysteine - Sickle Cell Disease, Sickle Cell Anemia | Phase 1 / Phase 2 | Completed | Bloodworks | 21 | 2013-03-01 | 2020-07-09 |
| Effects of HQK-1001 in Patients With Sickle Cell Disease HQK-1001, Placebo - Sickle Cell Disease, Sickle Cell Anemia | Phase 2 | Terminated | HemaQuest Pharmaceuticals Inc. | 77 | 2012-07-01 | 2015-03-18 |
| Losartan to Reverse Sickle Nephropathy Losartan - Nephropathy, Sickle Cell Anemia | Phase 2 | Completed | Children's Hospital Medical Center, Cincinnati | 36 | 2012-02-01 | 2020-09-29 |
| The Efficacy of Jobelyn (Sorghum Bicolor Extract)in the Treatment of Sickle Cell Anemia Paludrine + Folic Acid, Paludrine + Folic Acid + Jobelyn - Sickle Cell Anemia | Phase 1 / Phase 2 | Completed | Lagos State University | 150 | 2012-01-01 | 2012-10-10 |
| A Study of HQK-1001 in Patients With Sickle Cell Disease HQK-1001 - Sickle Cell Disease, Sickle Cell Anemia | Phase 2 | Completed | HemaQuest Pharmaceuticals Inc. | 52 | 2011-04-01 | 2013-06-19 |
Showing 20 of 38. Sign in to see all of them.
Anemia, Sickle Cell (38) · Thalassemia (6) · Genetic Diseases, Inborn (5) · Hematologic Diseases (4) · Hemoglobinopathies (4) · beta-Thalassemia (4) · Anemia (3) · Rare Diseases (3) · Anemia, Diamond-Blackfan (2) · Anemia, Aplastic (1) · Anemia, Hemolytic (1) · Anemia, Hemolytic, Congenital (1) · Burns (1) · Chest Pain (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1)
Anemia, Hemolytic (37) · Anemia, Hemolytic, Congenital (37) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (37) · Hemic and Lymphatic Diseases (37) · Anemia (35) · Hematologic Diseases (34) · Hemoglobinopathies (34) · Genetic Diseases, Inborn (33) · Pathological Conditions, Signs and Symptoms (6) · Pathologic Processes (4) · Thalassemia (4) · Bone Marrow Diseases (3) · Bone Marrow Failure Disorders (3) · Disease Attributes (3) · Anemia, Aplastic (2)
Hydroxyurea (8) · Alemtuzumab (5) · Cyclophosphamide (3) · fludarabine (3) · 2,2-dimethylbutyric acid (2) · Busulfan (2) · Glutamine (2) · Granulocyte Colony-Stimulating Factor (2) · Saline Solution (2) · Sirolimus (2) · senicapoc (2) · Acetylcholine (1) · Acetylcysteine (1) · Alendronate (1) · Bone Marrow Transplantation (1)
National Heart, Lung, and Blood Institute (NHLBI) (3) · Baylor College of Medicine (2) · Children's Hospital Medical Center, Cincinnati (2) · Dana-Farber Cancer Institute (2) · HemaQuest Pharmaceuticals Inc. (2) · National Institutes of Health Clinical Center (CC) (2) · Al-Neelain University (1) · Biossil Inc. (1) · Bloodworks (1) · Cephalon (1) · Children's National Research Institute (1) · David Rizzieri, MD (1) · Eli Lilly and Company (1) · Emmaus Medical, Inc. (1) · Fred Hutchinson Cancer Center (1)
United States (32) · Canada (5) · Jamaica (3) · Lebanon (3) · Egypt (2) · Germany (2) · Nigeria (2) · Turkey (Türkiye) (2) · United Kingdom (2) · Austria (1) · Bahrain (1) · Belgium (1) · Brazil (1) · France (1) · Israel (1)
Richard Ghalie, MD, MBA (2) · Yutaka Niihara, MD (2) · A O Dosunmu, M.D. (1) · Amal M Saeed, PhD (1) · Arthur L. Burnett, MD (1) · Barbara A Konkle, M.D. (1) · Courtney D Fitzhugh, M.D. (1) · Daniel B Kim-Shapiro, PhD (1) · David A. Rizzieri, MD (1) · David Nathan, MD (1) · Douglas V. Faller (1) · Eugene Paul Orringer (1) · Farid Boulad, MD (1) · Griffin P Rodgers, M.D. (1)
PMID 18192510, PMID 20955402, PMID 23828223, PMID 24677033, PMID 26719803, PMID 27619954, PMID 28331623, PMID 28589652, PMID 29296811, PMID 30956961, PMID 31316836, PMID 32188508, PMID 33660875, PMID 34917079, PMID 35226723, PMID 36240296, PMID 37428866, PMID 38268013, PMID 38775255, PMID 40062628, PMID 40780831, PMID 41026975, PMID 41253090, PMID 41871072, PMID 42133908, PMID 42224366
K23HL148310 (1), P50HL110790 (1), R34HL127162 (1), R37HL058091 (1), U01HL117659 (1)